Under-Eye Filler Gone Wrong: Tyndall Effect, Puffiness and Fixes

The Tyndall effect is a bluish discoloration that shows through thin skin when filler sits too close to the surface.

The Restylane Eyelight label describes the mechanism without using the word: injection that is too superficial in the thin periorbital skin "may result in contour irregularities and palpable lumps and/or bluish discolouration." The tear-trough literature uses the name Tyndall effect for the same blue appearance.

How often it happens depends on the study.

A 2023 meta-analysis of HA filler for tear-trough deformity — 31 reports covering 2,556 participants — pooled the rate of blue discoloration/Tyndall effect at 0.9%.

A UK single-practice series of 1,452 tear-trough applications in 583 patients, all placed with a blunt cannula between 2016 and 2020, reported a Tyndall effect in 3.3%.

The Eyelight label gives no rate at all.

Discoloration under the eyes is not always about filler depth, either: the same label warns that injecting the lower periorbital region in people with pre-existing pigmented dark circles may make the discoloration more prominent.

And it can arrive late — in a 2022 systematic review of 52 delayed complication cases after tear-trough filler, discoloration was the latest-appearing problem, at a mean of 52 months after injection.

Swelling is the reaction the trial data covers in most detail, including how long it lasted.

In the Restylane Eyelight trial, subjects' diaries after the initial injection most often reported tenderness (89.7%), swelling (85.0%), bruising (63.1%), redness (61.5%), pain (59.8%) and lumps/bumps (53.5%); swelling lasted 2–7 days in 76.6% and 14–28 days in 2.0%.

Those are diary figures for one product in a trial — not a prediction for any individual.

The label adds a specific warning for people prone to fluid retention: injection in patients with a pre-existing tendency toward edema may be associated with excessive swelling from fluid build-up.

A 2021 review of periocular fillers reports that 90% of adverse events around the eye are mild and resolve within 1 month — but that malar edema, a delayed swelling it describes as unique to the area around the eyes, occurred in 11% of patients.

The UK series tells the same story with longer tails: 10% reported swelling with a median duration of 4 weeks, half of edema cases resolved on their own after 4 weeks, and larger injected volumes were significantly linked to edema.

In the 2022 review of delayed complications, swelling was the most common delayed problem (42.3% of the 52 reported cases), with a mean onset of 16.8 months after injection.

How much filler counts as "too much" has no single answer, but one label draws a line: the Eyelight label limits treatment to up to 1 mL per side per session and recommends a follow-up session instead of a larger amount, because the safety of larger per-session amounts has not been established.

For comparison, the mean first-visit volume in the UK series was 0.34 mL per eye.

"Dent" is the reader's word — the label and the studies call these contour irregularities, places where the treated area is uneven rather than smooth.

The Eyelight label ties them to technique: too-superficial injection in thin periorbital skin may cause contour irregularities and palpable lumps.

In the Eyelight trial diaries, lumps/bumps appeared in 53.5% of subjects' reports after the initial injection.

The tear-trough studies report their own figures: the 2023 meta-analysis pooled contour irregularity/lumps at 5.3%, and the UK series reported contour irregularities in 4.6% — with larger volumes significantly linked to irregularities, as with edema.

Lumps can also be late.

In the 2022 review of 52 delayed complication cases, lumps or nodules were the second most common delayed problem (25.0%), xanthelasma-like reactions accounted for 17.3%, and migration for 7.7%.

Those percentages describe reported cases, not incidence rates in the general treated population.

Migration — filler moving from where it was placed — can also appear late, and the oculoplastic literature takes the possibility seriously: a 2021 review advises that prior filler — with possible migration or a Tyndall appearance — should be suspected in patients presenting for aesthetic evaluation, and notes that hyaluronidase injection is generally effective at reducing overcorrection or migration of HA filler in this area.

The Eyelight label's own framing of the worst outcomes is narrower than the word "botched" suggests: puffiness, lumps or swelling that caused negative cosmetic outcomes were noted as rare as well as correctable, and late-onset problems such as delayed inflammation or granulomas more than 2 years after injection are low in frequency but have been reported.

The specific fix for a hyaluronic acid filler problem is hyaluronidase, the enzyme that breaks HA down.

US products include Hylenex recombinant (human recombinant hyaluronidase) and Amphadase (purified bovine testicular hyaluronidase), both supplied as 150 USP units/mL single-dose vials.

Cleveland Clinic says hyaluronidase dissolves HA filler wherever it was placed — lips, cheeks and lower eyelids are its examples — but not silicone or other non-HA filler materials.

Dissolving filler is an off-label use.

The Hylenex and Amphadase labels list three FDA-approved uses — supporting subcutaneous fluid administration (hydration), increasing the dispersion and absorption of other injected drugs, and subcutaneous urography — and filler dissolving is on none of them, so it is not on any current US label for these products.

That includes the emergency use: treating a vascular occlusion with hyaluronidase is off-label too.

In the UK series, filler was dissolved in 1.9% of orbits, and one patient (0.17%) had a retrobulbar hemorrhage that was managed immediately with no lasting visual compromise.

What the appointment involves is documented for lips, where Cleveland Clinic says the treatment takes between 10 and 15 minutes, one or two visits usually suffice, some results are visible immediately, and full results can take up to two weeks.

Under the eyes, the oculoplastic review is the direct evidence: hyaluronidase is generally effective at reducing overcorrection or migration of HA filler in this area.

Expectations still need tempering — Juvéderm's Important Safety Information states that the effectiveness of removing any dermal filler has not been studied.

Hyaluronidase has its own label warnings: allergic reactions (urticaria or angioedema) have been reported in fewer than 0.1% of patients (a label rate from general medical use, not filler dissolving specifically), anaphylactic-like reactions have occurred rarely (reported after retrobulbar block or IV injection), known hypersensitivity to hyaluronidase is a contraindication, and the most frequently reported reactions are mild local ones — redness and pain at the injection site.

What was placed matters for the fix.

As of October 2026, four US filler products carry an FDA-approved under-eye (infraorbital hollow) indication: Juvéderm Volbella XC (2021), Restylane Eyelight (2023), Belotero Balance (+) Lidocaine (2023) and RHA Redensity Eye / Eye Lido (2026).

Any other filler used under the eyes — Restylane-L, Voluma, Radiesse and Sculptra are examples — is an off-label use there.

Prevention is the rest of the answer.

Allergan says Volbella XC should only be injected into the under-eye hollows by doctors who have completed its training for that treatment area, and its specialist finder marks trained doctors with a symbol.

The under-eye filler guide covers injector choice, approved products, sessions and cost, and the filler dissolving guide walks through the hyaluronidase process in detail.

One risk on this page is in a different category from the rest.

FDA tells patients to seek immediate medical attention for unusual pain, vision changes, a white, gray or blue appearance of skin near the injection site, or any signs of stroke during or shortly after filler injection.